Skip to main content
. 2022 Aug 30;13:5108. doi: 10.1038/s41467-022-32565-w

Fig. 2. Plasma FPV concentration of four uninfected NHPs.

Fig. 2

a Favipiravir pharmacokinetic parameters during treatment with 250 mg/kg BID i.v. on day 0 followed by 150 mg/kg BID s.c. for 14 days. b Longitudinal evolution of plasma FPV concentrations with respect to EC50 values obtained on ZIKV and SARS-CoV-2 given in refs. 7, 12. Source data are provided as a Source Data file.